Multimodel Anesthesia May Cut Opioid Usage After Head and Neck Cancer Surgery
Study authors analyzed the safety and efficacy of using MMA for patients undergoing head and neck surgery.
Head and Neck Cancer
HPV Vaccine Will Have Modest Impact on Oropharynx Cancer Incidence by 2045
However, reductions in oropharynx cancer incidence should be seen among young and middle-aged adults
Carboplatin Intensification Beneficial for Group 3 Medulloblastoma
Therapy intensification with carboplatin improved five-year event-free survival in children with high-risk group 3 medulloblastoma only
AAO/HNS Issue Guideline for Opioid Use After Otolaryngologic Surgery
Recommendations aim to improve postoperative pain control while reducing the risk for opioid use disorder.
New Dosing Regimen Approved for Erbitux in Colorectal, Head and Neck Cancer
The new dosing schedule is in addition to the approved weekly dosage regimen.
Tipifarnib Gets Breakthrough Tx Designation for Head and Neck Cancer
The FDA previously granted Fast Track designation to tipifarnib for this indication.
Physician Overlooks MRI, Then Claims Chiropractor Patient Should Have Read It
This month we look at a case where a jury was asked to hold a patient partially responsible for his own injury based on the fact that he had some medical background.
FDA Approves Keytruda for Tumor Mutational Burden-High Cancer
The accelerated approval was based on data from a prospectively-planned retrospective analysis of 10 cohorts of patients with various previously treated unresectable or metastatic solid tumors with TMB-H who were enrolled in the open-label phase 2 KEYNOTE-158 trial.
Gardasil 9 Approved to Prevent Certain HPV-Related Head and Neck Cancers
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
New Dosing Schedule Approved for All Keytruda Indications
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.
